Prudential Financial Inc. lifted its position in shares of Axovant Sciences Ltd (NASDAQ:AXON) by 164.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 212,280 shares of the biotechnology company’s stock after acquiring an additional 132,110 shares during the quarter. Prudential Financial Inc. owned 0.20% of Axovant Sciences worth $1,461,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. Bank of America Corp DE grew its position in Axovant Sciences by 38.9% during the first quarter. Bank of America Corp DE now owns 7,396 shares of the biotechnology company’s stock worth $111,000 after buying an additional 2,072 shares during the period. Legal & General Group Plc grew its position in Axovant Sciences by 20.2% during the second quarter. Legal & General Group Plc now owns 6,955 shares of the biotechnology company’s stock worth $162,000 after buying an additional 1,168 shares during the period. Russell Investments Group Ltd. grew its position in Axovant Sciences by 38.5% during the second quarter. Russell Investments Group Ltd. now owns 10,041 shares of the biotechnology company’s stock worth $233,000 after buying an additional 2,789 shares during the period. Voya Investment Management LLC acquired a new position in Axovant Sciences during the second quarter worth about $323,000. Finally, Atlantic Trust Group LLC acquired a new position in Axovant Sciences during the second quarter worth about $334,000. Institutional investors and hedge funds own 96.93% of the company’s stock.

Several research analysts have weighed in on the stock. Oppenheimer lowered shares of Axovant Sciences from an “outperform” rating to a “market perform” rating in a research report on Tuesday, September 26th. Evercore ISI restated an “outperform” rating and set a $9.00 target price (down from $30.00) on shares of Axovant Sciences in a research report on Tuesday, September 26th. HC Wainwright restated a “buy” rating and set a $11.00 target price on shares of Axovant Sciences in a research report on Friday, December 1st. Piper Jaffray Companies lowered shares of Axovant Sciences from an “overweight” rating to a “neutral” rating and lowered their target price for the stock from $32.00 to $9.00 in a research report on Tuesday, September 26th. Finally, UBS lowered shares of Axovant Sciences from an “outperform” rating to a “market perform” rating in a research report on Tuesday, September 26th. Four equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and six have assigned a buy rating to the company. Axovant Sciences has a consensus rating of “Hold” and a consensus price target of $14.13.

Shares of Axovant Sciences Ltd (NASDAQ:AXON) opened at $5.03 on Thursday. Axovant Sciences Ltd has a 1 year low of $4.60 and a 1 year high of $27.98. The company has a debt-to-equity ratio of 0.34, a quick ratio of 5.94 and a current ratio of 5.94.

TRADEMARK VIOLATION NOTICE: This article was originally reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this article on another website, it was illegally copied and republished in violation of U.S. and international copyright and trademark law. The original version of this article can be accessed at https://theolympiareport.com/2017/12/07/axovant-sciences-ltd-axon-stake-lifted-by-prudential-financial-inc.html.

About Axovant Sciences

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Want to see what other hedge funds are holding AXON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axovant Sciences Ltd (NASDAQ:AXON).

Institutional Ownership by Quarter for Axovant Sciences (NASDAQ:AXON)

Receive News & Ratings for Axovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd and related companies with Analyst Ratings Network's FREE daily email newsletter.